UK biotech Exscientia has terminated the employment of its founder and chief executive, Dr Andrew Hopkins, effective immediately, over what is described as “inappropriate
UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the
German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh